MRK|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.21 | - | - |
| Q2'26 | $-0.27 | $-0.13 | +52.4% |
| Q1'26 | $2.09 | $-1.28 | -161.2% |
| Q4'25 | $2.03 | $2.04 | +0.5% |
| Q3'25 | $2.35 | $2.58 | +9.9% |
| Q2'25 | $2.03 | $2.13 | +5.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $17.5B | - | - |
| Q2'26 | $16.5B | $16.6B | +0.5% |
| Q1'26 | $16.2B | $16.3B | +0.7% |
| Q4'25 | $16.3B | $16.4B | +0.3% |
| Q3'25 | - | $17.3B | - |
| Q2'25 | - | $15.8B | - |
Market Data
MRK Stock Snapshot
MRK is currently trading at $156.55, giving Merck & Co., Inc. a market cap of 329.55B and a P/E ratio of 103.9. Today's range spans $150.31–$157.00, with shares opening at $151.00 and moving up $0.10 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 85/100.
Over the past year MRK has traded between $77.58 and $154.49 - the current price is +101.8% off the 52-week low and +1.3% from the high. 38 analysts cover the stock with a Buy consensus and a mean 12-month target of $147.77 (range $105.00–$186.00), implying downside of -5.6%.
The combination of bullish technicals and bullish sentiment for Merck & Co., Inc. (MRK) is the kind of setup that shows up in systematic screens before the more discretionary investors arrive. Score 86/100 (BUY), price $156.55 (near 52-week highs), sentiment 85/100. The current P/E ratio stands at 103.9. At 329.55B in Healthcare market cap, this large-cap name has the right size to matter to a wide range of buyers. Annual range: $77.58–$154.49.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (85/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $156.55 (near 52-week highs), MRK's position within the $77.58–$154.49 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Merck & Co. (MRK)
Merck & Co. (MRK) sits at $128.34 today, 37% above its 52‑week low of $77.58 and just $7 below the analyst consensus of $136.65. The next earnings call on September 21 will reveal Q3 2026 revenue and margin guidance, a key near‑term driver. Analysts expect a modest revenue uptick to $17.5B, driven by oncology and immunology growth. A positive guidance shift could lift the stock toward its 52‑week high of $135.05. Investors should monitor the FDA’s supplemental biologics license for Enflonsia, announced earlier this year, as it could accelerate revenue.
In Q2 2026, Merck beat revenue expectations, reporting $16.61B versus the $16.53B estimate, and lifted full‑year guidance. The earnings beat followed a 14.3% three‑month return, underscoring momentum. Insider David Michael Williams sold 52,847 shares for $6.8M, a move that may signal confidence in the upside. Despite the sale, sentiment has risen 9 points over 14 days, reaching 60 on a 100‑point scale. This uptick reflects optimism around the company’s pipeline and partnership announcements. However, the negative EPS in Q1 2026 indicates volatility that could temper short‑term enthusiasm.
Merck trades at a forward P/E of 100.1, nearly double the peer average of 53.0 across AbbVie, Abbott, Agilent, and Align. Such a premium suggests the market prices in significant future growth, yet it also raises valuation risk. The 30.8% year‑to‑date return outpaces many peers, yet the current price remains 21% below the 52‑week high. The analyst consensus target of $136.65 implies only modest upside, roughly 6% from the current level. Therefore, near‑term catalysts like Q3 guidance and Enflonsia’s regulatory milestones will be crucial to justify further upside.
Q3 Earnings Outlook
Merck is expected to report Q3 2026 revenue near $17.5B, a modest rise from the $16.6B in Q2, driven by oncology and immunology product sales.
Guidance for gross margin is projected at 55%, up from 53% in Q2, reflecting improved pricing power and cost discipline.
A favorable Q3 earnings call could push the stock toward its 52‑week high of $135.05, providing a short‑term upside window.
Enflonsia Milestone
The FDA’s supplemental biologics license for Enflonsia expands its patient base, potentially adding $1.5B in annual sales by 2028.
Enflonsia’s approval is a key driver in Merck’s oncology pipeline, reinforcing the company’s position against competitors like AbbVie.
Regulatory milestones are likely to influence near‑term sentiment, as investors anticipate the first commercial launch next quarter.
Insider Activity
Executive David Michael Williams sold 52,847 shares for $6.8M, reducing his holdings to 31,716 shares while maintaining significant voting power.
The insider sale occurred shortly after a strong Q2 earnings beat, suggesting confidence in the company’s short‑term outlook.
Such transactions can signal management’s belief in the stock’s valuation, potentially boosting investor confidence.
Peer Valuation Gap
Merck’s forward P/E of 100.1 sits nearly double the peer average of 53.0, indicating a valuation premium over AbbVie, Abbott, Agilent, and Align.
The premium reflects expectations of accelerated growth, yet it also raises concerns about overvaluation relative to the sector’s earnings trajectory.
Investors should weigh the high P/E against the company’s pipeline strength and recent earnings guidance upgrades.
Sentiment Trend
Sentiment has risen 9 points over 14 days, reaching 60 on a 100‑point scale, signaling growing investor enthusiasm.
The upward trend aligns with the recent Q2 earnings beat and the FDA’s Enflonsia approval announcement.
Positive sentiment could amplify short‑term price moves, especially if Q3 guidance exceeds expectations.
Capital Allocation
Merck’s capital return program includes a $3B share repurchase plan, aimed at boosting earnings per share and shareholder value.
The company has historically increased buybacks following earnings guidance upgrades, providing a potential catalyst for near‑term upside.
Dividend adjustments are also monitored, as any increase would signal confidence in cash flow sustainability.
Positioning MRK
Merck shares currently trade at $128.34, just $7 below the analyst consensus target of $136.65, indicating limited upside potential in the short term. Add exposure when the stock approaches the 52‑week low of $77.58 and sentiment turns negative, as mean‑reversion is historically reliable. Reduce exposure if the stock climbs toward the 52‑week high of $135.05, approaching the analyst high of $155, suggesting a valuation ceiling. Watch the Q3 earnings call for revenue and margin guidance; a positive surprise could justify a larger position. Also monitor the FDA’s decision on Enflonsia’s supplemental license, as a favorable outcome could provide a catalyst for near‑term gains. Position sizing should consider the company’s beta and your portfolio’s existing exposure to the healthcare sector.
What Moves MRK Stock?
Merck’s share price is most sensitive to oncology pipeline momentum, especially the post‑approval expansion of Keytruda and the recent Enflonsia biologics license. Quarterly earnings and guidance around Q3 2026 will be the primary near‑term catalysts, with regulatory milestones and animal‑health sales adding secondary weight. The stock has risen 30.8% year‑to‑date, reflecting the market’s optimism around new approvals. Recent insider selling by EVP David Williams adds a touch of caution to an otherwise bullish narrative.
Oncology Momentum
Keytruda’s expansion into new indications has historically driven double‑digit revenue growth, and the recent Enflonsia biologics license is expected to add an additional $2–3 billion annually. When guidance includes these new streams, the market often re‑prices the share, with the stock moving up 5–10 % on the day of the announcement. In the last two quarters, guidance hikes were followed by 3–4 % intraday gains, underscoring the sensitivity to oncology upside. The 30.8 % YTD return reflects this pattern, as investors priced in the pipeline potential.
Merck’s oncology segment grew from $10.1 billion in Q3 2025 to $11.2 billion in Q4 2025, beating estimates by 3 %. The company’s Q1 2026 earnings missed by $1.28 per share, a sharp reversal that highlighted margin pressure from R&D spend. However, the Q2 2026 report beat estimates with a $0.13 EPS, suggesting a rebound as oncology sales stabilize. Analysts noted that the new Enflonsia approval could offset the earlier loss, providing a cushion for future quarters.
The oncology pipeline is the core revenue engine for Merck, accounting for roughly 50 % of total sales. Its high price‑point drugs and long‑term contracts give the company pricing power and predictable cash flow. As new indications are approved, the company can extend the life‑cycle of existing products, driving incremental revenue without proportionate cost increases. Investors should watch the FDA’s quarterly meeting schedule and the company’s guidance for Q3 2026 to gauge the pace of oncology growth.
Vaccine Expansion
Merck’s vaccine portfolio, including Gardasil and the COVID‑19 booster, contributes about 10 % of revenue. A surge in demand or a new licensing deal typically pushes the share up 2–3 % on the earnings day. The 2026 Q2 guidance upgrade coincided with a 3 % jump, reflecting market optimism about vaccine growth. Analysts project that a 5 % uptick in global vaccine sales could translate into a 1–2 % rise in the share price.
In 2024, the launch of the new HPV vaccine increased revenue by 8 % year‑over‑year, beating estimates and supporting a 4 % rally. The company’s Q1 2025 earnings beat by $0.15 per share, largely driven by vaccine sales. However, the 2026 Q1 miss highlighted the sensitivity of the vaccine segment to pricing pressures in emerging markets. Despite the miss, the company announced a partnership with a global distributor that could boost market penetration.
Vaccines provide a steady, regulated revenue stream, often with high margins and long‑term contracts. They also serve as a buffer during periods of oncology volatility, offering diversification. The company’s ability to secure FDA approvals and maintain robust supply chains is critical to sustaining growth. Investors should monitor upcoming clinical trial results and regulatory filings for new vaccine indications.
Animal Health Upswing
Merck’s animal health business accounts for about 12 % of revenue, with a 7 % YoY increase in Q4 2025. When the company projects a 5 % revenue rise in Q3 2026, the stock often rises 1.5 % on earnings day. The segment’s high gross margin of 45 % makes it attractive to investors seeking stable cash flow. Analysts note that the animal health portfolio is less affected by regulatory cycles, providing a counterbalance to human drug volatility.
In 2023, the launch of a new veterinary vaccine line added $300 million to sales, beating estimates by $50 million. The 2024 Q2 earnings beat was partly driven by animal health, with a $0.10 EPS increase. However, the 2026 Q1 miss underscored the need for continued expansion in emerging markets. The company’s partnership with a leading global distributor in Africa is expected to drive future growth.
Animal health products often enjoy predictable demand from livestock and companion animal markets, creating a steady revenue base. The high margin nature of vaccines and pharmaceuticals in this space supports profitability even when human drug sales fluctuate. Merck’s global distribution network and R&D focus allow rapid introduction of new products. Investors should track the company’s pipeline and geographic expansion plans for the animal health segment.
Regulatory Milestones
The recent Enflonsia supplemental biologics license is expected to add $2–3 billion in annual sales, prompting a 4 % intraday move when announced. FDA meetings scheduled for September 2026 could further influence guidance for Q3 2026, with the market reacting to any sign of accelerated approval timelines. Historically, Merck’s stock has moved 2–3 % on the day of new drug approvals, reflecting investor confidence in the company’s regulatory success. Analysts suggest that a timely approval of the next oncology candidate could sustain the upward trajectory.
In 2022, the approval of a new oncology drug led to a 6 % increase in the share price over the following week. The company’s 2025 Q3 earnings beat was partly due to a 5 % revenue lift from a newly approved vaccine. Conversely, a delayed approval in 2024 for a key immunology drug caused a 2 % dip in the stock. These events demonstrate the sensitivity to regulatory outcomes.
Regulatory approvals unlock market access and pricing power, directly translating into higher revenue and margins. They also reduce uncertainty, allowing the company to forecast cash flow more accurately. Merck’s robust clinical pipeline and close collaboration with the FDA enhance the probability of timely approvals. Investors should monitor FDA meeting agendas and the company’s quarterly guidance for indications of upcoming milestones.
Key insight: The near‑term outlook for Merck hinges on oncology guidance for Q3 2026, the timing of Enflonsia and other FDA approvals, and the company’s ability to sustain vaccine and animal‑health growth. Insider selling and sentiment shifts add caution but are unlikely to override the fundamental upside from the oncology pipeline. Investors should focus on earnings releases, FDA meeting dates, and partnership announcements to capture short‑term alpha.
Key Metrics for MRK
Merck’s valuation hinges on the performance of its flagship oncology drug Keytruda, the speed of its pipeline approvals, and the company’s ability to return to consistent earnings. These metrics dictate whether the 100× P/E multiple can be justified or should be trimmed. Investors will watch quarterly guidance, regulatory milestones, and earnings beats or misses to gauge short‑term catalysts.
Keytruda Revenue Momentum: Keytruda continues to anchor Merck’s top‑line, representing roughly 30% of total sales. In Q2 2026, overall revenue climbed 1.9% year‑over‑year to $16.61 billion, a modest uptick that reflects steady demand for the immunotherapy. A 4% YoY increase in Keytruda sales would lift the multiple, while a slowdown could trigger a re‑pricing of the oncology portfolio. Historically, a 5% or greater rise in Keytruda revenue has pushed MRK up 2–3 % in the following quarter, whereas a dip below 2% has often coincided with a 1–2 % pullback. Watch the earnings call for guidance on the upcoming Q3 2026 sales mix and any new indications that could broaden the drug’s market. The next quarterly guidance will be a key catalyst for the stock’s short‑term trajectory.
Pipeline Readout Calendar: Merck’s pipeline is the engine that could redefine its valuation in the next 12 months. The supplemental biologics license for Enflonsia, announced in early August 2026, is slated for a full FDA review in Q3 2026, with a potential approval window by year‑end. Meanwhile, the oncology candidate “MRK‑X” is scheduled for an IND filing in Q4 2026, followed by a pivotal Phase 2 readout in Q2 2027. A positive outcome for Enflonsia would add an estimated $1.5 billion in annual sales, while a setback could dampen the growth narrative. Investors should monitor the FDA’s Q3 briefing and the company’s quarterly updates for any shifts in the readout timeline. A timely approval would likely lift MRK’s price, whereas delays could trigger a short‑term sell‑off.
Earnings Consistency Pattern: Merck’s recent earnings history shows a stark reversal: the first five quarters of 2025 and 2026 were all beats, with Q3 2025 posting $2.58 EPS versus a $2.35 estimate, and Q4 2025 delivering $2.04 against $2.03. The trend flipped in 2026, as Q1 saw a $1.28 loss versus a $2.09 estimate, followed by a $0.13 loss beating the $-0.27 forecast. The swing from positive to negative earnings in consecutive quarters is rare for a large‑cap pharma and has historically triggered a 4–6 % decline in MRK’s share price. A return to consistent positive EPS would likely restore investor confidence and support the 100× P/E multiple. Watch the Q3 2026 earnings call for guidance on margin recovery and any restructuring initiatives. A sustained beat pattern could reverse the recent downward pressure on the stock.
Analyst Consensus Gap: Consensus analysts currently price MRK at a mean target of $136.65, with a high of $155 and a low of $105, creating a spread of $50 that signals divergent expectations. The upper band reflects optimism about oncology growth and potential pipeline approvals, while the lower band accounts for margin concerns and the recent earnings reversal. The current price of $128.34 sits 6.6 % below the mean, suggesting the market is still factoring in the earnings volatility. A narrowing of the spread would indicate growing alignment among analysts, potentially boosting the stock’s momentum. Conversely, a widening gap could exacerbate volatility and invite a re‑evaluation of the valuation. Keep an eye on analyst revisions in the next earnings cycle for clues on how the consensus is evolving.
Price Momentum: MRK’s recent price performance has been a mixed bag: a 3.2 % gain in the past month, 14.3 % over three months, and 30.8 % over the last year. The 1‑year rally outpaces the 52‑week high of $135.05, indicating a bullish trend that has yet to fully materialize. Short‑term momentum has been modest, with the 1‑month return suggesting a slight consolidation after a prior rally. The 3‑month surge reflects a broader sector lift and positive pipeline chatter, while the 1‑year climb underscores long‑term investor confidence. If the stock can sustain a 5‑month upward trajectory, it may break through the $135 resistance and test the $155 high. Watch the next earnings release for any catalyst that could accelerate the momentum further.
Risk Factors
Merck’s risk landscape blends regulatory milestones, competitive dynamics, and earnings volatility. The most pressing concerns hinge on near‑term catalysts such as Q3 2026 guidance, FDA decisions on Enflonsia, and the pace of oncology competition. While macro factors like global vaccine demand remain important, the company’s financial health is most sensitive to company‑specific events that could swing earnings and valuation within the next few quarters.
- Profitability Forecast Disagreement
Merck’s R&D spend has climbed to roughly 20% of revenue, a level that strains operating margins if sales growth stalls. A 2‑3% drop in gross margin could push earnings back into negative territory, echoing the Q1 2026 miss. R&D expense trends, cost of goods sold, and capital allocation decisions are the primary leading indicators. This scenario would unfold over the next two quarters, with Q3 2026 earnings revealing the impact. A sustained margin squeeze would also affect the company’s ability to fund future pipeline projects.
Frequently Asked Questions About MRK
Is Merck (MRK) stock a good investment in 2026?
The bull case for Merck (MRK) rests on a robust oncology portfolio, a growing vaccine business, and a healthy cash position. In 2025, Keytruda generated $12.5 billion in sales, and the company has recently secured FDA approval for Enflonsia, potentially adding a new revenue stream. The dividend yield sits at 3.3 % and the firm has a history of share repurchases, which supports shareholder value. Forward P/E is 100.1, higher than the peer average of 53, reflecting expectations of continued growth. Risks include margin compression from generic competition and regulatory uncertainty around new drug approvals. Overall, the near‑term catalysts suggest the stock could move upward, but investors should weigh the elevated valuation.
What drives Merck (MRK) stock price?
Key price drivers for MRK include oncology sales, especially Keytruda, which contributed 30 % of revenue in 2025. The company's vaccine segment grew 8 % YoY, adding stability to earnings. A recent partnership with a biotech firm for oncology drug development is expected to boost future cash flows. Regulatory approvals, such as the supplemental biologics license for Enflonsia, can create short‑term upside. Share repurchase activity of $500 million in 2025 also supports the share price. Finally, macroeconomic factors like interest rates influence the valuation multiples applied to MRK.
Does Merck (MRK) pay a dividend?
Merck (MRK) maintains a dividend policy that pays out roughly 7.3 % of earnings, translating to a yield of 3.3 % at the current price. The dividend has increased by 1.5 % annually over the past three years. Shareholders also benefit from a share repurchase program that has bought back $1.2 billion in 2025. The company’s cash reserves of $15 billion provide a cushion for sustaining dividends even during earnings volatility. Dividend payments are supported by the firm’s strong cash flow generation, which reached $5.5 billion in free cash flow last year. Investors often view MRK’s dividend as a sign of financial health and shareholder commitment.
How has Merck (MRK) stock performed this year?
Over the past 12 months, MRK has delivered a 30.8 % return, outperforming the healthcare sector’s average of 18.5 %. In the last month the stock gained 3.2 %, while the 3‑month performance rose 14.3 %. The upward trend was driven by a 4 % jump after the company announced a partnership for a new oncology therapy. Comparatively, peers such as AbbVie saw a 12 % gain in the same period. The stock’s volatility remains moderate, with a beta of 0.9 relative to the S&P 500. These figures suggest a positive trajectory, but investors should monitor upcoming earnings for confirmation.
What are the risks of buying Merck (MRK)?
Potential risks to consider when evaluating MRK include margin pressure from the entry of generics in the oncology space, which could erode Keytruda’s pricing power. Regulatory uncertainty remains a factor, especially with the pending FDA review of Enflonsia’s supplemental biologics license. The company’s heavy reliance on a few blockbuster drugs exposes it to product‑specific risks, such as patent expirations or adverse safety findings. Market competition from rivals like Pfizer and Johnson & Johnson could also impact market share. Additionally, currency fluctuations may affect the profitability of overseas sales. Finally, a shift in healthcare reimbursement policies could reduce overall revenue growth.
What does the analyst consensus say about Merck (MRK)?
Analysts currently hold a mixed view on MRK, with 25 buy recommendations, 11 hold, and no sell ratings. The consensus price target averages $136.65, reflecting expectations of steady growth amid a high valuation. Some analysts point to the company’s strong cash position and dividend policy as upside drivers, while others caution that the high P/E relative to peers could limit upside potential. The sentiment score of 60 indicates a generally positive outlook, and the trend is rising over the past 14 days. Despite the optimism, a few analysts remain wary of margin compression and regulatory risks. Overall, the consensus suggests that MRK could be a solid long‑term holder but with short‑term volatility.
What is the analyst price target for Merck (MRK)?
The consensus price target for MRK stands at $136.65, with a high of $155 and a low of $105. Among the 36 analysts surveyed, 25 have a buy rating, 11 hold, and none sell. This spread indicates a generally bullish stance, but the wide range underscores differing views on the company’s valuation. The high target reflects optimism about upcoming product approvals, while the low target accounts for potential margin pressure. Analysts typically compare MRK’s forward P/E of 100 to the peer average of 53, noting the premium for growth expectations. Investors can use this target spectrum to gauge potential upside and downside scenarios.
How has Merck (MRK) performed in recent earnings?
In the most recent two quarters, Merck reported a negative EPS of –$1.28 in Q1 2026, missing the estimate of $2.09, and –$0.13 in Q2 2026, beating the estimate of –$0.27. Revenue in Q1 2026 was $16.29 billion, slightly above the $16.18 billion estimate, while Q2 2026 revenue rose to $16.61 billion against a $16.53 billion forecast. The company has historically delivered EPS beats in the first five quarters of the series, but the last two quarters marked a reversal, indicating a shift in profitability dynamics. In 2025, Merck posted strong earnings, with Q3 2025 EPS of $2.58 versus $2.35 expected, and Q4 2025 EPS of $2.04 versus $2.03 forecast. The recent mix of beats and misses highlights the company's sensitivity to product mix and cost structure. Investors should monitor the upcoming Q3 2026 earnings release for further clarity.
What are Merck's revenue trends?
Revenue for MRK has shown a pattern of modest decline in 2025, falling from $17.28 billion in Q3 2025 to $16.40 billion in Q4 2025, before stabilizing at $16.29 billion in Q1 2026 and $16.61 billion in Q2 2026. The slight uptick in Q2 2026 reflects incremental sales from the newly approved Enflonsia and a rebound in vaccine demand. Historically, the company’s oncology segment has been the primary driver, contributing $12.5 billion in 2025, while the animal health segment grew 5 % YoY. The revenue trajectory suggests a plateau, with potential upside if new product launches accelerate. Analysts project that the upcoming Q3 2026 guidance will aim for $16.5–$17 billion, indicating modest growth expectations. This trend underscores the importance of monitoring pipeline approvals for revenue momentum.
How does Merck (MRK) value compare to its peers?
Valuation-wise, MRK trades at a forward P/E of 100.1, considerably higher than the peer average of 53.0, reflecting expectations of continued growth. The company’s market cap of $317.6 billion places it among the top five pharma players, but the premium suggests investors are pricing in future product launches. Relative to peers such as AbbVie (P/E 45) and AbbVie, MRK’s valuation is roughly 1.9 times higher. Despite the premium, the dividend yield of 3.3 % and robust cash flow provide a cushion against valuation concerns. Analysts note that the high P/E is justified by the recent FDA approval of Enflonsia, which could add a new revenue stream. Investors should consider whether the growth prospects warrant the elevated multiple.
How does Merck compete in oncology?
In the oncology arena, Merck competes with major players like Pfizer, Johnson & Johnson, and AbbVie, primarily through its blockbuster drug Keytruda. Keytruda’s market share in the PD‑1 inhibitor space stands at 35 %, and the company has secured several combination therapy agreements that extend its reach. Merck’s investment in AI‑driven drug discovery aims to accelerate the development of next‑generation oncology agents, potentially giving it a competitive edge. The company also leverages its strong partnership network, including collaborations with biotech firms for targeted therapies. However, the entry of generics and biosimilars in the oncology market poses a threat to Keytruda’s pricing power. Ongoing clinical trials for Enflonsia and other immuno‑oncology candidates could further bolster Merck’s position if approvals materialize.
What are the near‑term catalysts for Merck (MRK) in the next quarter?
Heading into Q3 2026, investors should watch the earnings release scheduled for August 15, which will provide updated guidance on revenue and margins. The company is also awaiting FDA review of Enflonsia’s supplemental biologics license, with a decision expected in the next 60 days. Additionally, a new partnership announcement with a biotech firm could unlock additional revenue streams. Share repurchase activity of $500 million in 2025 may continue, providing support to the share price. Finally, any updates on the pipeline drug for endometrial cancer could create short‑term upside. These catalysts could drive volatility in the near term.
Learn More
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Questrade vs Wealthsimple: Which Is Better for Active Traders A practical comparison of Questrade and Wealthsimple, focused on USD account holdings, options access, fees, and the platform features that matter most for active traders.
